Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.48 |
| ▸ | KDM5C | P41229 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 5/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | KDM5A | P29375 | 2/20 | 0.40 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.40 |
| ▸ | KDM4A | O75164 | 1/20 | 0.40 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14825887 | 1.00 | KDM4C (0.48) | KDM4CKDM5CBCHEOPRM1KDM5A | |
| SCHEMBL14814197 | 0.94 | KDM4C (0.53) | KDM4CKDM5CBCHEOPRM1KDM5A | |
| SCHEMBL14813910 | 0.91 | BCHE (0.55) | KDM4CKDM5CBCHEOPRM1SLC6A3 | |
| SCHEMBL14813761 | 0.91 | KDM5C (0.51) | KDM4CKDM5CBCHEOPRM1SLC6A3 | |
| SCHEMBL14813979 | 0.91 | KDM5C (0.51) | KDM4CKDM5CBCHEOPRM1SLC6A3 | |
| SCHEMBL12064979 | 0.91 | KDM5C (0.51) | KDM4CKDM5CBCHEOPRM1SLC6A3 | |
| SCHEMBL14846069 | 0.88 | BCHE (0.46) | BCHEOPRM1 | |
| SCHEMBL14825882 | 0.88 | BCHE (0.46) | BCHEOPRM1 | |
| SCHEMBL14825395 | 0.88 | BCHE (0.52) | KDM4CKDM5CBCHEOPRM1 | |
| SCHEMBL14825436 | 0.85 | BCHE (0.47) | KDM4CKDM5CBCHEOPRM1ACKR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9365553-B2 | Heterocyclic compound and H1 receptor antagonist | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2016-06-14 | — | — | US | disclosed |
| US-9365553-B2 | Heterocyclic compound and H1 receptor antagonist | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2016-06-14 | — | — | US | disclosed |
| EP-2578569-B1 | HETEROCYCLIC RING COMPOUND AND H1 RECEPTOR ANTAGONIST | ASKA PHARM CO LTD (JP) | 2015-10-28 | — | — | EP | disclosed |
| EP-2578569-A1 | HETEROCYCLIC RING COMPOUND AND H1 RECEPTOR ANTAGONIST | ASKA Pharmaceutical Co., Ltd. (JP) | 2013-04-10 | — | — | EP | disclosed |
| US-20130085127-A1 | HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST | ASKA PHARMACEUTICAL CO., LTD (JP) | 2013-04-04 | — | — | US | disclosed |
| US-20130085127-A1 | HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST | ASKA PHARMACEUTICAL CO., LTD (JP) | 2013-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085127-A1 | HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST | HRH2, HRH4, HRH1 | KDM4C 3070/4885KDM5C 2930/4885BCHE 2942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.